市場調査レポート

商品コード

1552699

非ホジキンリンパ腫（NHL）治療の世界市場：産業分析、規模、シェア、成長、動向、予測、2024-2034年

Non-Hodgkin's Lymphoma Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

出版日: 2024年07月11日
発行: Transparency Market Research
ページ情報: 英文 135 Pages
納期: 2～10営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 5,795 834,827円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷物の取り扱いは電子版のライセンス範囲に準拠します。

PDF (Multi-user License)

USD 8,795 1,267,007円

レポートPDFを同一の部署内・課内の5名の方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷物の取り扱いは電子版のライセンス範囲に準拠します。

PDF (Corporate License)

USD 11,795 1,699,187円

レポートPDFを企業内すべての方に使用頂けるライセンスです。ご利用人数の制限はありません。 PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷物の取り扱いは電子版のライセンス範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.06円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

非ホジキンリンパ腫（NHL）治療市場- 調査範囲

TMRの調査レポート「非ホジキンリンパ腫（NHL）治療の世界市場」は、2024年から2034年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。当レポートでは、2024年を基準年、2034年を予測年として、2018年から2034年までの世界の非ホジキンリンパ腫（NHL）治療市場の収益と予測を提供しています。また、2024年から2034年までの世界の非ホジキンリンパ腫（NHL）治療市場の複合年間成長率（CAGR %）も掲載しています。

本レポートは広範な調査を経て作成されています。1次調査では、アナリストが主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。2次調査では、主要企業の製品資料、アニュアルレポート、プレスリリース、関連資料などを参照し、非ホジキンリンパ腫（NHL）治療市場を推察しました。

市場スナップショット
2023年の市場規模	80億米ドル
2034年の市場規模	186億米ドル
CAGR	8%

本レポートでは、世界の非ホジキンリンパ腫（NHL）治療市場の競合情勢について掘り下げています。世界の非ホジキンリンパ腫（NHL）治療市場で事業を展開する主要企業が特定され、各企業が様々な属性でプロファイルされています。企業概要、財務状況、最近の動向、SWOTなどが、本レポートで紹介されている世界の非ホジキンリンパ腫（NHL）治療市場におけるプレイヤーの属性です。

市場企業-競合マトリックス（企業階層と規模別）
市場シェア分析：企業別（2023）
企業プロファイル
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Sanofi S.A.
- Pfizer Inc.
- GSK plc
- Novartis AG
- Bayer AG
- Eli Lilly and Company
- Merck & Co., Inc.
- AbbVie Inc.
- AstraZeneca plc
- Johnson & Johnson Pvt. Ltd.

図表

List of Tables

Table 01: Global Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Treatment Therapy, 2020-2034
Table 02: Global Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Indication Type, 2020-2034
Table 03: Global Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 04: Global Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 05: Global Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Region, 2020-2034
Table 06: North America Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Country, 2020-2034
Table 07: North America Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Treatment Therapy, 2020-2034
Table 08: North America Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Indication Type, 2020-2034
Table 9: North America Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 10: North America Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 11: Europe Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 12: Europe Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Treatment Therapy, 2020-2034
Table 13: Europe Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Indication Type, 2020-2034
Table 14: Europe Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 15: Europe Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 16: Asia Pacific Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 17: Asia Pacific Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Treatment Therapy, 2020-2034
Table 18: Asia Pacific Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Indication Type, 2020-2034
Table 19: Asia Pacific Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 20: Asia Pacific Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 21: Latin America Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 22: Latin America Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Treatment Therapy, 2020-2034
Table 23: Latin America Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Indication Type, 2020-2034
Table 24: Latin America Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 25: Latin America Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 26: Middle East & Africa Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 27: Middle East & Africa Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Treatment Therapy, 2020-2034
Table 28: Middle East & Africa Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Indication Type, 2020-2034
Table 29: Middle East & Africa Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034
Table 30: Middle East & Africa Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast, by End-user, 2020-2034

List of Figures

Figure 01: Global Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn), by Region, 2023 and 2034
Figure 02: Global Non-Hodgkin's Lymphoma Therapeutics Market Revenue (US$ Bn), by Treatment Therapy, 2023
Figure 03: Global Non-Hodgkin's Lymphoma Therapeutics Market Value Share, by Treatment Therapy, 2023
Figure 04: Global Non-Hodgkin's Lymphoma Therapeutics Market Revenue (US$ Bn), by Indication Type, 2023
Figure 05: Global Non-Hodgkin's Lymphoma Therapeutics Market Value Share, by Indication Type, 2023
Figure 06: Global Non-Hodgkin's Lymphoma Therapeutics Market Revenue (US$ Bn), by Route of Administration, 2023
Figure 07: Global Non-Hodgkin's Lymphoma Therapeutics Market Value Share, by Route of Administration, 2023
Figure 08: Global Non-Hodgkin's Lymphoma Therapeutics Market Revenue (US$ Bn), by End-user, 2023
Figure 09: Global Non-Hodgkin's Lymphoma Therapeutics Market Value Share, by End-user, 2023
Figure 10: Global Non-Hodgkin's Lymphoma Therapeutics Market Value Share, by Region, 2023
Figure 11: Global Non-Hodgkin's Lymphoma Therapeutics Market Value (US$ Bn) Forecast, 2020-2034
Figure 12: Global Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Treatment Therapy, 2023 and 2034
Figure 13: Global Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Treatment Therapy, 2024-2034
Figure 14: Global Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Indication Type, 2023 and 2034
Figure 15: Global Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Indication Type, 2024-2034
Figure 16: Global Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 17: Global Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 18: Global Non-Hodgkin's Lymphoma Therapeutics Market Revenue (US$ Bn), by End-user, 2023
Figure 19: Global Non-Hodgkin's Lymphoma Therapeutics Market Value Share, by End-user, 2023
Figure 20: Global Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Region, 2023 and 2034
Figure 21: Global Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Region, 2024-2034
Figure 22: North America Non-Hodgkin's Lymphoma Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 23: North America Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Country, 2024-2034
Figure 24: North America Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Country, 2023 and 2034
Figure 25: North America Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Treatment Therapy, 2023 and 2034
Figure 26: North America Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Indication Type, 2023 and 2034
Figure 27: North America Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 28: North America Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 29: North America Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Treatment Therapy, 2024-2034
Figure 30: North America Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Indication Type, 2024-2034
Figure 31: North America Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 32: North America Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by End-user, 2024-2034
Figure 33: Europe Non-Hodgkin's Lymphoma Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 34: Europe Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 35: Europe Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 36: Europe Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Treatment Therapy, 2023 and 2034
Figure 37: Europe Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Indication Type, 2023 and 2034
Figure 38: Europe Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 39: Europe Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 40: Europe Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Treatment Therapy, 2024-2034
Figure 41: Europe Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Indication Type, 2024-2034
Figure 42: Europe Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 43: Europe Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by End-user, 2024-2034
Figure 44: Asia Pacific Non-Hodgkin's Lymphoma Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 45: Asia Pacific Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 46: Asia Pacific Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 47: Asia Pacific Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Treatment Therapy, 2023 and 2034
Figure 48: Asia Pacific Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Indication Type, 2023 and 2034
Figure 49: Asia Pacific Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 50: Asia Pacific Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 51: Asia Pacific Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Treatment Therapy, 2024-2034
Figure 52: Asia Pacific Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Indication Type, 2024-2034
Figure 53: Asia Pacific Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 54: Asia Pacific Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by End-user, 2023-2034
Figure 55: Latin America Non-Hodgkin's Lymphoma Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 56: Latin America Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 57: Latin America Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 58: Latin America Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Treatment Therapy, 2023 and 2034
Figure 59: Latin America Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Indication Type, 2023 and 2034
Figure 60: Latin America Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 61: Latin America Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 62: Latin America Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Treatment Therapy, 2024-2034
Figure 63: Latin America Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Indication Type, 2024-2034
Figure 64: Latin America Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 65: Latin America Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by End-user, 2024-2034
Figure 66: Middle East & Africa Non-Hodgkin's Lymphoma Therapeutics Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 67: Middle East & Africa Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 68: Middle East & Africa Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 69: Middle East & Africa Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Treatment Therapy, 2023 and 2034
Figure 70: Middle East & Africa Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Indication Type, 2023 and 2034
Figure 71: Middle East & Africa Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by Route of Administration, 2023 and 2034
Figure 72: Middle East & Africa Non-Hodgkin's Lymphoma Therapeutics Market Value Share Analysis, by End-user, 2023 and 2034
Figure 73: Middle East & Africa Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Treatment Therapy, 2024-2034
Figure 74: Middle East & Africa Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Indication Type, 2024-2034
Figure 75: Middle East & Africa Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by Route of Administration, 2024-2034
Figure 76: Middle East & Africa Non-Hodgkin's Lymphoma Therapeutics Market Attractiveness Analysis, by End-user, 2024-2034

Product Code: TMRGL2668

Non-Hodgkin's Lymphoma Therapeutics Market - Scope of Report

TMR's report on the global non-Hodgkin's lymphoma therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global non-Hodgkin's lymphoma therapeutics market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global non-Hodgkin's lymphoma therapeutics market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the non-Hodgkin's lymphoma therapeutics market.

Market Snapshot
Market Value in 2023	US$ 8 Bn
Market Value in 2034	US$ 18.6 Bn
CAGR	8%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global non-Hodgkin's lymphoma therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global non-Hodgkin's lymphoma therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global non-Hodgkin's lymphoma therapeutics market.

The report delves into the competitive landscape of the global non-Hodgkin's lymphoma therapeutics market. Key players operating in the global non-Hodgkin's lymphoma therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global non-Hodgkin's lymphoma therapeutics market profiled in this report.

Key Questions Answered in Global non-Hodgkin's lymphoma therapeutics Market Report:

What is the sales/revenue generated by non-Hodgkin's lymphoma therapeutics across all regions during the forecast period?
What are the opportunities in the global non-Hodgkin's lymphoma therapeutics market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2034?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?

Non-Hodgkin's Lymphoma Therapeutics Market - Research Objectives and Research Approach

The comprehensive report on the global non-Hodgkin's lymphoma therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global non-Hodgkin's lymphoma therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global non-Hodgkin's lymphoma therapeutics market.

1. Preface

1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Non-Hodgkin's Lymphoma Therapeutics Market

4. Market Overview

4.1. Introduction
- 4.1.1. Product Definition
- 4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
4.4. Global Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast, 2020-2034

5. Key Insights

5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry

6. Global Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast, by Treatment Therapy

6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Treatment Therapy, 2020-2034
- 6.3.1. Chemotherapy
- 6.3.2. Targeted Therapy
- 6.3.3. Immunotherapy
- 6.3.4. Others (Radiation Therapy, etc.)
6.4. Market Attractiveness, by Treatment Therapy

7. Global Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast, by Indication Type

7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Indication Type, 2020-2034
- 7.3.1. B-Cell Lymphomas
- 7.3.2. T-Cell Lymphomas
7.4. Market Attractiveness, by Indication Type

8. Global Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast, by Route of Administration

8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Route of Administration, 2020-2034
- 8.3.1. Oral
- 8.3.2. Parenteral
8.4. Market Attractiveness, by Route of Administration

9. Global Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast, by End-user

9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2020-2034
- 9.3.1. Hospital Pharmacies
- 9.3.2. Retail Pharmacies
- 9.3.3. Online Pharmacies
9.4. Market Attractiveness, by End-user

10. Global Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast, by Region

10.1. Key Findings
10.2. Market Value Forecast, by Region, 2020-2034
- 10.2.1. North America
- 10.2.2. Europe
- 10.2.3. Asia Pacific
- 10.2.4. Latin America
- 10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region

11. North America Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast

11.1. Introduction
- 11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment Therapy, 2020-2034
- 11.2.1. Chemotherapy
- 11.2.2. Targeted Therapy
- 11.2.3. Immunotherapy
- 11.2.4. Others (Radiation Therapy, etc.)
11.3. Market Attractiveness, by Treatment Therapy
11.4. Market Value Forecast, by Indication Type, 2020-2034
- 11.4.1. B-Cell Lymphomas
- 11.4.2. T-Cell Lymphomas
11.5. Market Attractiveness, by Indication Type
11.6. Market Value Forecast, by Route of Administration, 2020-2034
- 11.6.1. Oral
- 11.6.2. Parenteral
11.7. Market Attractiveness, by Route of Administration
11.8. Market Value Forecast, by End-user, 2020-2034
- 11.8.1. Hospital Pharmacies
- 11.8.2. Retail Pharmacies
- 11.8.3. Online Pharmacies
11.9. Market Attractiveness, by End-user
11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
- 11.10.1. U.S.
- 11.10.2. Canada
11.11. Market Attractiveness Analysis
- 11.11.1. By Treatment Therapy
- 11.11.2. By Indication Type
- 11.11.3. By Route of Administration
- 11.11.4. By End-user
- 11.11.5. By Country

12. Europe Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast

12.1. Introduction
- 12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment Therapy, 2020-2034
- 12.2.1. Chemotherapy
- 12.2.2. Targeted Therapy
- 12.2.3. Immunotherapy
- 12.2.4. Others (Radiation Therapy, etc.)
12.3. Market Attractiveness, by Treatment Therapy
12.4. Market Value Forecast, by Indication Type, 2020-2034
- 12.4.1. B-Cell Lymphomas
- 12.4.2. T-Cell Lymphomas
12.5. Market Attractiveness, by Indication Type
12.6. Market Value Forecast, by Route of Administration, 2020-2034
- 12.6.1. Oral
- 12.6.2. Parenteral
12.7. Market Attractiveness, by Route of Administration
12.8. Market Value Forecast, by End-user, 2020-2034
- 12.8.1. Hospital Pharmacies
- 12.8.2. Retail Pharmacies
- 12.8.3. Online Pharmacies
12.9. Market Attractiveness, by End-user
12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
- 12.10.1. Germany
- 12.10.2. U.K.
- 12.10.3. France
- 12.10.4. Italy
- 12.10.5. Spain
- 12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
- 12.11.1. By Treatment Therapy
- 12.11.2. By Indication Type
- 12.11.3. By Route of Administration
- 12.11.4. By End-user
- 12.11.5. By Country/Sub-region

13. Asia Pacific Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast

13.1. Introduction
- 13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment Therapy, 2020-2034
- 13.2.1. Chemotherapy
- 13.2.2. Targeted Therapy
- 13.2.3. Immunotherapy
- 13.2.4. Others (Radiation Therapy, etc.)
13.3. Market Attractiveness, by Treatment Therapy
13.4. Market Value Forecast, by Indication Type, 2020-2034
- 13.4.1. B-Cell Lymphomas
- 13.4.2. T-Cell Lymphomas
13.5. Market Attractiveness, by Indication Type
13.6. Market Value Forecast, by Route of Administration, 2020-2034
- 13.6.1. Oral
- 13.6.2. Parenteral
13.7. Market Attractiveness, by Route of Administration
13.8. Market Value Forecast, by End-user, 2020-2034
- 13.8.1. Hospital Pharmacies
- 13.8.2. Retail Pharmacies
- 13.8.3. Online Pharmacies
13.9. Market Attractiveness, by End-user
13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
- 13.10.1. China
- 13.10.2. Japan
- 13.10.3. India
- 13.10.4. Australia & New Zealand
- 13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
- 13.11.1. By Treatment Therapy
- 13.11.2. By Indication Type
- 13.11.3. By Route of Administration
- 13.11.4. By End-user
- 13.11.5. By Country/Sub-region

14. Latin America Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast

14.1. Introduction
- 14.1.1. Key Findings
14.2. Market Value Forecast, by Treatment Therapy, 2020-2034
- 14.2.1. Chemotherapy
- 14.2.2. Targeted Therapy
- 14.2.3. Immunotherapy
- 14.2.4. Others (Radiation Therapy, etc.)
14.3. Market Attractiveness, by Treatment Therapy
14.4. Market Value Forecast, by Indication Type, 2020-2034
- 14.4.1. B-Cell Lymphomas
- 14.4.2. T-Cell Lymphomas
14.5. Market Attractiveness, by Indication Type
14.6. Market Value Forecast, by Route of Administration, 2020-2034
- 14.6.1. Oral
- 14.6.2. Parenteral
14.7. Market Attractiveness, by Route of Administration
14.8. Market Value Forecast, by End-user, 2020-2034
- 14.8.1. Hospital Pharmacies
- 14.8.2. Retail Pharmacies
- 14.8.3. Online Pharmacies
14.9. Market Attractiveness, by End-user
14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
- 14.10.1. Brazil
- 14.10.2. Mexico
- 14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
- 14.11.1. By Treatment Therapy
- 14.11.2. By Indication Type
- 14.11.3. By Route of Administration
- 14.11.4. By End-user
- 14.11.5. By Country/Sub-region

15. Middle East & Africa Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast

15.1. Introduction
- 15.1.1. Key Findings
15.2. Market Value Forecast, by Treatment Therapy, 2020-2034
- 15.2.1. Chemotherapy
- 15.2.2. Targeted Therapy
- 15.2.3. Immunotherapy
- 15.2.4. Others (Radiation Therapy, etc.)
15.3. Market Attractiveness, by Treatment Therapy
15.4. Market Value Forecast, by Indication Type, 2020-2034
- 15.4.1. B-Cell Lymphomas
- 15.4.2. T-Cell Lymphomas
15.5. Market Attractiveness, by Indication Type
15.6. Market Value Forecast, by Route of Administration, 2020-2034
- 15.6.1. Oral
- 15.6.2. Parenteral
15.7. Market Attractiveness, by Route of Administration
15.8. Market Value Forecast, by End-user, 2020-2034
- 15.8.1. Hospital Pharmacies
- 15.8.2. Retail Pharmacies
- 15.8.3. Online Pharmacies
15.9. Market Attractiveness, by End-user
15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
- 15.10.1. GCC Countries
- 15.10.2. South Africa
- 15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
- 15.11.1. By Treatment Therapy
- 15.11.2. By Indication Type
- 15.11.3. By Route of Administration
- 15.11.4. By End-user
- 15.11.5. By Country/Sub-region

16. Competition Landscape

16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2023)
16.3. Company Profiles
- 16.3.1. Mylan N.V.
  - 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.1.2. Product Portfolio
  - 16.3.1.3. Financial Overview
  - 16.3.1.4. SWOT Analysis
  - 16.3.1.5. Strategic Overview
- 16.3.2. Teva Pharmaceutical Industries Ltd.
  - 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.2.2. Product Portfolio
  - 16.3.2.3. Financial Overview
  - 16.3.2.4. SWOT Analysis
  - 16.3.2.5. Strategic Overview
- 16.3.3. Sanofi S.A.
  - 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.3.2. Product Portfolio
  - 16.3.3.3. Financial Overview
  - 16.3.3.4. SWOT Analysis
  - 16.3.3.5. Strategic Overview
- 16.3.4. Pfizer Inc.
  - 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.4.2. Product Portfolio
  - 16.3.4.3. Financial Overview
  - 16.3.4.4. SWOT Analysis
  - 16.3.4.5. Strategic Overview
- 16.3.5. GSK plc
  - 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.5.2. Product Portfolio
  - 16.3.5.3. Financial Overview
  - 16.3.5.4. SWOT Analysis
  - 16.3.5.5. Strategic Overview
- 16.3.6. Novartis AG
  - 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.6.2. Product Portfolio
  - 16.3.6.3. Financial Overview
  - 16.3.6.4. SWOT Analysis
  - 16.3.6.5. Strategic Overview
- 16.3.7. Bayer AG
  - 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.7.2. Product Portfolio
  - 16.3.7.3. Financial Overview
  - 16.3.7.4. SWOT Analysis
  - 16.3.7.5. Strategic Overview
- 16.3.8. Eli Lilly and Company
  - 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.8.2. Product Portfolio
  - 16.3.8.3. Financial Overview
  - 16.3.8.4. SWOT Analysis
  - 16.3.8.5. Strategic Overview
- 16.3.9. Merck & Co., Inc.
  - 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.9.2. Product Portfolio
  - 16.3.9.3. Financial Overview
  - 16.3.9.4. SWOT Analysis
  - 16.3.9.5. Strategic Overview
- 16.3.10. AbbVie Inc.
  - 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.10.2. Product Portfolio
  - 16.3.10.3. Financial Overview
  - 16.3.10.4. SWOT Analysis
  - 16.3.10.5. Strategic Overview
- 16.3.11. AstraZeneca plc
  - 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.11.2. Product Portfolio
  - 16.3.11.3. Financial Overview
  - 16.3.11.4. SWOT Analysis
  - 16.3.11.5. Strategic Overview
- 16.3.12. Johnson & Johnson Pvt. Ltd.
  - 16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
  - 16.3.12.2. Product Portfolio
  - 16.3.12.3. Financial Overview
  - 16.3.12.4. SWOT Analysis
  - 16.3.12.5. Strategic Overview

非ホジキンリンパ腫（NHL）治療の世界市場：産業分析、規模、シェア、成長、動向、予測、2024-2034年

Non-Hodgkin's Lymphoma Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

非ホジキンリンパ腫（NHL）治療市場- 調査範囲

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

第5章 主要洞察

第6章 世界の市場分析と予測：療法別

第7章 世界の市場分析と予測：適応症タイプ別

第8章 世界の市場分析と予測：投与経路別

第9章 世界の市場分析と予測：エンドユーザー別

第10章 世界の市場分析と予測：地域別

第11章 北米の市場分析と予測

第12章 欧州の市場分析と予測

第13章 アジア太平洋地域の市場分析と予測

第14章 ラテンアメリカの市場分析と予測

第15章 中東・アフリカの市場分析と予測

第16章 競合情勢

List of Tables

List of Figures

Non-Hodgkin's Lymphoma Therapeutics Market - Scope of Report

Key Questions Answered in Global non-Hodgkin's lymphoma therapeutics Market Report:

Non-Hodgkin's Lymphoma Therapeutics Market - Research Objectives and Research Approach

Table of Contents

1. Preface

2. Assumptions and Research Methodology

3. Executive Summary: Global Non-Hodgkin's Lymphoma Therapeutics Market

4. Market Overview

5. Key Insights

6. Global Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast, by Treatment Therapy

7. Global Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast, by Indication Type

8. Global Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast, by Route of Administration

9. Global Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast, by End-user

10. Global Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast, by Region

11. North America Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast

12. Europe Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast

13. Asia Pacific Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast

14. Latin America Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast

15. Middle East & Africa Non-Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast

16. Competition Landscape

第1章序文

第2章前提条件と調査手法

第3章エグゼクティブサマリー：世界市場

第4章市場概要

第5章主要洞察

第6章世界の市場分析と予測：療法別

第7章世界の市場分析と予測：適応症タイプ別

第8章世界の市場分析と予測：投与経路別

第9章世界の市場分析と予測：エンドユーザー別

第10章世界の市場分析と予測：地域別

第11章北米の市場分析と予測

第12章欧州の市場分析と予測

第13章アジア太平洋地域の市場分析と予測

第14章ラテンアメリカの市場分析と予測

第15章中東・アフリカの市場分析と予測

第16章競合情勢